Tivozanib: First Global Approval.

Article Details

Citation
Copy to clipboard

Kim ES

Tivozanib: First Global Approval.

Drugs. 2017 Nov;77(17):1917-1923. doi: 10.1007/s40265-017-0825-y.

PubMed ID
28971328 [ View in PubMed
]
Abstract

Tivozanib (Fotivda((R))) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC. Tivozanib is at various stages of development in other countries for advanced RCC and advanced solid tumours. This article summarizes the milestones in the development of tivozanib leading to this first global approval in Europe for the treatment of adults with advanced RCC.

DrugBank Data that Cites this Article

Drugs